How Tirzepatide Works: The Dual GLP-1/GIP Mechanism Explained

Tirzepatide (Mounjaro, Zepbound) is pharmacologically distinct from semaglutide and other GLP-1 medications. It is a dual agonist — a single molecule that activates two separate hormone receptors simultaneously. Understanding what each receptor does, and why the combination outperforms single-agonist drugs in trials, requires looking at both pathways.

The GLP-1 component: familiar territory

The GLP-1 receptor agonism in tirzepatide works through the same pathways as semaglutide:

• Stimulates insulin secretion in response to elevated blood glucose
• Suppresses glucagon (which would otherwise drive blood sugar higher)
• Slows gastric emptying, extending the feeling of fullness after meals
• Acts on appetite-regulating centres in the hypothalamus and brainstem, reducing hunger and food preoccupation

These effects are well-established from over a decade of GLP-1 receptor agonist use in clinical practice.

The GIP component: what it adds

GIP — glucose-dependent insulinotropic polypeptide — is a gut hormone released by the K-cells of the small intestine in response to food intake. It was identified as an incretin (a hormone that stimulates insulin release) decades ago. For a long time, GIP was thought to be less relevant than GLP-1 for weight management. Tirzepatide's clinical results prompted a significant reassessment.

What GIP appears to do in the context of a dual agonist:

• Augment insulin secretion — GIP has its own insulin-stimulating effect that appears to work additively with GLP-1 receptor activation
• Act on adipose tissue — GIP receptors are expressed in fat cells. Activation appears to influence how the body handles fat storage and utilisation, though the precise mechanism is still being mapped
• Enhance appetite suppression — the combination of GLP-1 and GIP receptor activation appears to produce greater appetite reduction than GLP-1 agonism alone, likely through effects on both peripheral and central pathways
• Reduce nausea — interestingly, GIP receptor activation may partially offset the nausea that pure GLP-1 agonists can cause, which may explain why tirzepatide's tolerability is at least comparable to semaglutide despite producing more weight loss

Why GIP alone does not produce weight loss

One of the counterintuitive findings from the research: GIP receptor agonism alone does not produce meaningful weight loss. GIP infusions in isolation can actually promote fat storage in some contexts. The weight-loss effect appears to emerge specifically from the combination of GLP-1 and GIP receptor co-activation — the dual agonism creates something greater than the sum of its parts. How exactly this happens at a molecular level is an active area of research.

What the trial data shows about the added effect

The SURMOUNT-1 trial compared tirzepatide at three doses against placebo over 72 weeks in adults with obesity but without diabetes. Results:

• 5 mg tirzepatide: Average 15% body weight loss
• 10 mg tirzepatide: Average 19.5% body weight loss
• 15 mg tirzepatide: Average 20.9% body weight loss
• Placebo: Average 3.1% body weight loss

At the highest dose, nearly 1 in 3 participants lost 25% or more of their body weight — outcomes that had not been seen with any previous obesity pharmacotherapy. For comparison, the STEP-1 trial of semaglutide 2.4 mg showed average 14.9% weight loss.

The side effect profile

Because both GLP-1 and GIP receptors are involved in gastric motility, tirzepatide shares the same core side effect profile as semaglutide: nausea, vomiting, diarrhoea, constipation, and reduced appetite, most prominent during titration. The dual mechanism may partially moderate GI side effects (some evidence suggests this), but the practical experience is similar to semaglutide for most patients.

What this means for the choice between tirzepatide and semaglutide

Mechanistically, tirzepatide's dual agonism gives it an efficacy advantage on average. But "average" covers enormous individual variation. Some patients respond as well or better to semaglutide; others see dramatically better results on tirzepatide. Coverage, cost, and availability often determine the practical choice more than the pharmacology does.

This article describes mechanisms based on published research as of May 2026. The science around GIP's role in weight regulation is evolving. Drug selection should always involve a licensed prescriber who knows your full history.